TOP TIERMARKET NEWSWIRE

News & sentiment

ROCKET PHARMACEUTICA (RCKT) — News & AI sentiment

ROCKET PHARMACEUTICA (RCKT) news roundup. 14 stories aggregated over the last 30 days. Average 30-day sentiment is 58.9/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 7 sales totalling $432K — net selling of $432K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

0

7d stories

0

30d stories

14

avg sentiment 58.9/100

Insider net (90d)

$432K

0 buys · 7 sells

Congress (90d)

0

0 buys · 0 sells

RCKT news in the last 24 hours, 7 days, 30 days and 90 days

How much RCKT coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	RCKT stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	0	—	no coverage
Last 30 days	14	58.9/100	RCKT headlines →
Last 90 days	42	59.1/100	RCKT headlines →

Latest stories on RCKT

Why is Rock Tech Lithium stock climbing today?

Investing.com Markets63 · neutralgeneral

Oct 16

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

StockTitan52 · neutralproduct/pr

Oct 15

Rocket Pharma upgraded at Goldman Sachs on Danon disease therapy

Seeking Alpha67 · bullishanalyst

Oct 8

Goldman Sachs upgrades Rocket Pharmaceuticals stock rating on Danon disease drug progress

Investing.com Analyst Ratings64 · neutralanalyst

Oct 8

Rocket Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs

The Fly63 · neutralanalyst

Oct 8

Rocket Pharma updates progress on RP-A501 for Danon disease

Seeking Alpha63 · neutralproduct/pr

Oct 7

Rocket Pharmaceuticals highlights FDA-aligned Phase 2 trial of RP-A501

The Fly63 · neutralproduct/pr

Oct 7

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

StockTitan63 · neutralproduct/pr

Oct 7

Cantor Fitzgerald reiterates Rocket Pharmaceuticals stock rating

Investing.com Analyst Ratings50 · neutralanalyst

Oct 7

Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript

Seeking Alpha56 · neutralproduct/pr

Oct 7

ROCKET PHARMACEUTICALS, INC. (RCKT) files 8-K

SEC 8-K50 · neutralgeneral

Oct 6

Rocket Pharmaceuticals secures $150M credit facility from Hercules Capital

The Fly56 · neutralgeneral

Oct 6

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

StockTitan56 · neutralgeneral

Oct 6

Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus — The Week’s Biotech Watchlist

Stocktwits News58 · neutralproduct/pr

Oct 5

Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design

Seeking Alpha67 · bullishanalyst

Sep 16

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Stocktwits News73 · bullishanalyst

Sep 16

Rocket Pharmaceuticals upgraded to Buy from Hold at Needham

The Fly61 · neutralanalyst

Sep 16

Needham upgrades Rocket Pharmaceuticals after FDA reaffirms Danon study design

The Fly63 · neutralanalyst

Sep 16

Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

Sep 15

Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript

Seeking Alpha56 · neutralgeneral

Sep 15

Rocket Pharmaceuticals Shares Rise 8% After FDA Alignment on Danon Disease Trial

InvestorsHub67 · bullishgeneral

Sep 15

Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights

Stocktwits News63 · neutralgeneral

Sep 15

Why is Rocket Pharmaceuticals stock down 5% today?

Investing.com Markets35 · bearishgeneral

Sep 15

Rocket Pharmaceuticals stock jumps on FDA trial alignment

Investing.com Markets65 · bullishproduct/pr

Sep 15

Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial

Morningstar73 · bullishproduct/pr

Sep 15

Open RCKT in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →